• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, October 4, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Immunity boosting treatment enhances CAR-T cell therapy for blood cancers

Bioengineer by Bioengineer
June 13, 2022
in Cancer
Reading Time: 5 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are approved by the Food and Drug Administration to treat certain types of leukemia, lymphoma and multiple myeloma. Still, some patients’ tumors don’t respond well to these therapies, and many patients who do well initially later see their cancers return.

Immunity boosting treatment enhances CAR-T cell therapy for blood cancers

Credit: MICHAEL RETTIG/BURSKY CENTER FOR HUMAN IMMUNOLOGY & IMMUNOTHERAPY PROGRAMS

Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are approved by the Food and Drug Administration to treat certain types of leukemia, lymphoma and multiple myeloma. Still, some patients’ tumors don’t respond well to these therapies, and many patients who do well initially later see their cancers return.

Now, a new study by researchers at Washington University School of Medicine in St. Louis shows that additional treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of these genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells.

The mouse study — published June 13 in the journal Nature Communications — suggests promise for a phase 1 clinical trial at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trial is investigating a long-acting genetically modified type of IL-7 in conjunction with CAR-T cells targeting CD19, a B cell antigen in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Siteman is the coordinating center and one of four sites across the country participating in the trial.

“Many researchers are trying different strategies to enhance the function of CAR-T cells in treating blood cancers,” said senior author John F. DiPersio, MD, PhD, the Virginia E. & Sam J. Golman Professor of Medicine and director of the Division of Oncology. “We’re interested in IL-7 because we know it is a major driver of T cell expansion. The body makes IL-7 naturally to ramp up the number of T cells when a person gets sick, for example. When we give a long-acting type of IL-7 to tumor-bearing immunodeficient mice soon after CAR-T cell treatment, we see a dramatic expansion of these CAR-T cells greater than ten-thousandfold compared to mice not receiving IL-7.  These CAR-T cells also persist longer and show dramatically increased anti-tumor activity.”

CAR-T cells are manufactured using the body’s normal T cells, either from the patient or a donor. The CAR-T cells are genetically modified to specifically target a protein on the surface of the cancer cells. The targeting helps the CAR-T cells find the cancer cells, which are masters at evading immune attack. The therapy can be highly effective, but sometimes the CAR-T cells aren’t able to expand enough to kill all of the cancer, or they become overstimulated, “exhausting” their ability to function, resulting in their loss of anti-tumor effectiveness.

With these problems in mind, the researchers — including first author Miriam Y. Kim, MD, an assistant professor of medicine, and co-senior author Matthew L. Cooper, PhD, an adjunct assistant professor of medicine — were interested in whether they could harness the body’s natural way of boosting T cell numbers to enhance the therapy. But natural IL-7 normally disappears from the body quickly. Therefore, DiPersio and his team tested a modified form of IL-7 that circulates in the body for weeks, making it much more effective at supporting the CAR-T cell expansion.

Investigating two different models of B cell lymphoma in mice, the researchers showed that mice receiving CAR-T cells and long-acting IL-7 survived almost six times longer than mice receiving CAR-T cells alone. Mice treated with CAR-T cells alone survived for about one month after therapy. All mice that received long-acting IL-7 soon after the CAR-T cell treatment were still living at the end of an experimental time frame of 175 days. Further, tumor sizes in the mice that had received CAR-T cells and IL-7 were dramatically reduced, to the point of being undetectable in the majority of mice by day 35.

“In mice that received the CAR-T cells alone, the disease is controlled briefly,” DiPersio said. “But by week three, the tumor starts to return. And by week four, they start to look like the control mice that didn’t receive any active therapy. But by adding long-acting IL-7, the numbers of CAR-T cells just explode, and those mice lived beyond the time frame we set for our experiment. Our study also suggests that it may be possible to fine-tune the expansion of the CAR-T cells by controlling the number of IL-7 doses that we give.”

Washington University research laid the groundwork for using IL-7 to boost the immune system to treat disease, including its use with CAR-T cells. In addition, Richard S. Hotchkiss, MD, a professor of anesthesiology, of medicine and of surgery, and his team have studied IL-7 for its use in stimulating T cells to fight sepsis, a life-threatening response to infection. Research from the Brain Tumor Center at Siteman also has shown promise for the use of long-acting IL-7 to enhance T cells in treating glioblastoma, an aggressive brain cancer.

###

This work was supported by the National Cancer Institute of the National Institutes of Health (NIH), grant numbers R35 CA210084 and P50 CA171963; the Siteman Investment Program; Alex’s Lemonade Stand Foundation through a Northwestern Mutual Young Investigator Award; Washington University SPORE in Leukemia Developmental Research Award; and a Dean’s Scholars Award from the Washington University Division of Physician-Scientists.

DiPersio, Kim, Cooper, and co-authors Karl W. Staser, Julie O’Neal and Byung Ha Lee are inventors of a patent on the use of IL-7 to enhance CAR-T cell function. 

Kim MY et al. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR-T cells expansion, persistence and anti-tumor activity. Nature Communications. June 13, 2022. DOI: 10.1038/s41467-022-30860-0.

Washington University School of Medicine’s 1,700 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, and currently is No. 4 in research funding from the National Institutes of Health (NIH). Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.



Journal

Nature Communications

DOI

10.1038/s41467-022-30860-0

Subject of Research

Animals

Article Title

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR-T cells expansion, persistence and anti-tumor activity

Article Publication Date

13-Jun-2022

COI Statement

DiPersio, Kim, Cooper, and co-authors Karl W. Staser, Julie O’Neal and Byung Ha Lee are inventors of a patent on the use of IL-7 to enhance CAR-T cell function.

Share12Tweet8Share2ShareShareShare2

Related Posts

Kishore Guda

Case Western Reserve University and University Hospitals researchers awarded five-year, $11.2 million federal grant to study esophagus cancers

October 4, 2023
Dr. Justin Balko

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

October 4, 2023

BGI Genomics breaks new ground in Saudi Arabian precision medicine

October 4, 2023

Avatars to help tailor glioblastoma therapies

October 4, 2023

POPULAR NEWS

  • blank

    Microbe Computers

    59 shares
    Share 24 Tweet 15
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    35 shares
    Share 14 Tweet 9
  • Fossil spines reveal deep sea’s past

    34 shares
    Share 14 Tweet 9
  • Scientists go ‘back to the future,’ create flies with ancient genes to study evolution

    75 shares
    Share 30 Tweet 19

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Translational Plant Sciences Center sows seeds for new research

Case Western Reserve University and University Hospitals researchers awarded five-year, $11.2 million federal grant to study esophagus cancers

Revealing the ‘sweet secrets’ of coronavirus cell entry

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 56 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In